Efficacy and safety of 40 mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single‐center retrospective cohort study
In this study, we examined the efficacy of 40 mg of osimertinib administered every other day. In this single-center, retrospective study, we evaluated patients with NSCLC harboring anEGFR mutation in whom treatment was initiated with 40 mg osimertinib every other day at our institution between May 2016 and June 2023. The major outcome was the duration of administering 40 mg osimertinib every other day. Six patients with NSCLC were evaluated. The median duration of 40 mg osimertinib intake every other day was 12.6 months. F our of the six patients weighed below 50 kg, and four experienced weight loss. Additiona...
Source: Thoracic Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Ayumu Otsuki,
Naoki Inoshima,
Kentaro Tochigi,
Hiroyuki Ito,
Kei Nakashima Tags: BRIEF REPORT Source Type: research
Factors associated with prolonged progression ‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer
ConclusionsWe found thatEGFR-mutated NSCLC patients receiving first-line afatinib were prone to shorter PFS if they had distant organ metastasis, especially liver metastasis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 27, 2024 Category: Cancer & Oncology Authors: Li ‐Chung Chiu,
Ping‐Chih Hsu,
Chin‐Chou Wang,
How‐Wen Ko,
Scott Chih‐Hsi Kuo,
Jia‐Shiuan Ju,
Pi‐Hung Tung,
Allen Chung‐Cheng Huang,
Cheng‐Ta Yang Tags: ORIGINAL ARTICLE Source Type: research
Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system
ConclusionThe newly proposed grading system based on four pathological factors (presence of STAS, and percentage of lepidic, micropapillary, and solid subtypes) exhibits high accuracy and good reproducibility in the prognostic stratification of stage I lung adenocarcinoma patients. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 26, 2024 Category: Cancer & Oncology Authors: Shuaibo Wang,
Ye Li,
Xujie Sun,
Jiyan Dong,
Li Liu,
Jingbo Liu,
Ruanqi Chen,
Feng Li,
Tiange Chen,
Xiang Li,
Guotong Xie,
Jianming Ying,
Qiang Guo,
Yousheng Mao,
Lin Yang Tags: ORIGINAL ARTICLE Source Type: research
Prognostic value and relapse pattern of HER2 ‐low in hormone receptor‐positive breast cancer
ConclusionsNo significant difference in DFS and OS between the HER2-low group and the HER2-zero group was observed. Patients with HER2 IHC 1+ and 0 tend to develop bone metastasis. The HER2-low group had a more obvious second peak in mortality. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 26, 2024 Category: Cancer & Oncology Authors: Tong Wei,
Yikun Kang,
Xue Wang,
Jian Yue,
Binghe Xu,
Peng Yuan Tags: ORIGINAL ARTICLE Source Type: research
Triptolide inhibits esophageal squamous cell carcinoma progression by regulating the circNOX4/miR ‐153‐3p/SATB1 signaling pathway
ConclusionTriptolide could hinder ESCC progression, which was mainly achieved by regulating the circNOX4/miR-153-3p/SATB1 axis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Hanping Liang,
Weibi Che,
Fengyuan Peng,
Huilong Chen,
Xihao Xie,
Bomeng Wu Tags: ORIGINAL ARTICLE Source Type: research
Implication of IZUMO2 in the cell ‐in‐cell phenomenon: A potential therapeutic target for triple‐negative breast cancer
ConclusionThe findings highlight the importance of IZUMO2 on TNBC cells in facilitating the cell-in-cell phenomenon by A-Tregs. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 23, 2024 Category: Cancer & Oncology Authors: Toshiya Higashi,
Chiemi Saigo,
Wakana Chikaishi,
Hirokatsu Hayashi,
Yuki Hanamatsu,
Manabu Futamura,
Nobuhisa Matsuhashi,
Tamotsu Takeuchi Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - January 23, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer
ConclusionOur study suggests that the efficacy of ICIs in addition to chemotherapy may be poor in patients with NE marker-negative SCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 20, 2024 Category: Cancer & Oncology Authors: Yuko Iida,
Kazushige Wakuda,
Takuya Kawata,
Meiko Morita,
Motoki Sekikawa,
Kosei Doshita,
Michitoshi Yabe,
Hiroaki Kodama,
Keita Miura,
Noboru Morikawa,
Nobuaki Mamesaya,
Haruki Kobayashi,
Ryo Ko,
Akira Ono,
Hirotsugu Kenmotsu,
Tateaki Nait Tags: ORIGINAL ARTICLE Source Type: research
Real ‐world survival outcomes of immunotherapy for advanced non‐small cell lung cancer: A single‐center retrospective review
ConclusionReal-world survival outcomes of immunotherapy for advanced NSCLC are comparable to the existing literature in this single center study. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Gopika Punchhi,
Abdulkadir Hussein,
Swati Kulkarni Tags: ORIGINAL ARTICLE Source Type: research
With regard to the original article “A case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma”
(Source: Thoracic Cancer)
Source: Thoracic Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Yuki Hanamatsu,
Yuki Yada,
Koyo Shirahashi,
Tamotsu Takeuchi Tags: LETTER TO THE EDITOR Source Type: research
A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer
ConclusionVTE risk prediction models for patients with lung cancer have received attention for no more than 5 years. The included model shows a good predictive effect and may help identify the risk population of VTE at an early stage. In the future, it is necessary to improve data modeling and statistical analysis methods, develop predictive models with good performance and low risk of bias, and focus on external validation and recalibration of models. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 18, 2024 Category: Cancer & Oncology Authors: Yan Wang,
Qiuyue Li,
Yanjun Zhou,
Yiting Dong,
Jinping Li,
Tao Liang Tags: REVIEW Source Type: research
Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion
ConclusionAmong patients withEGFR-mutation positive NSCLC, the evidence of MPE has little effect on survival with osimertinib. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 16, 2024 Category: Cancer & Oncology Authors: Ayu Kiritani,
Yoshiaki Amino,
Ken Uchibori,
Takahiro Akita,
Yuhei Harutani,
Shinsuke Ogusu,
Ryosuke Tsugitomi,
Ryo Manabe,
Ryo Ariyasu,
Satoru Kitazono,
Noriko Yanagitani,
Makoto Nishio Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - January 15, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Rechallenge of immune checkpoint inhibitors in advanced non ‐small cell lung cancer
AbstractImmune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to...
Source: Thoracic Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Gen Lin,
Zhijie Wang,
Qian Chu,
Yi Hu,
Dingzhi Huang,
Jun Wang,
Fan Yang,
Wenzhao Zhong,
Chengzhi Zhou,
Bo Zhu,
Xinghao Ai,
Baoshan Cao,
Yabing Cao,
Mingqiu Chen,
Xiaohui Chen,
Tianqing Chu,
Jianchun Duan,
Yun Fan,
Yong Fang,
Shuitu Fen Tags: CLINICAL GUIDELINE Source Type: research
A very rare case of spontaneous regression of basaloid squamous cell carcinoma of the lung
Here, we report a case of spontaneous regression of basaloid squamous cell carcinoma of the lung. To the best of our knowledge, spontaneous regression of basaloid squamous cell carcinoma of the lung has not previously been reported. AbstractSpontaneous regression of non-small cell lung cancer is relatively rare. Here, we present a very rare case of spontaneous regression of lung cancer which occurred in a patient with basaloid squamous cell lung cancer. To the best of our knowledge, this is the first report of such a case. A 76-year old man was referred to our hospital with nodules in the right upper lobe determined by che...
Source: Thoracic Cancer - January 14, 2024 Category: Cancer & Oncology Authors: Sachie Koike,
Takayuki Shiina,
Keiichiro Takasuna,
Akane Kato,
Takuma Atagi,
Toshitsugu Nakamura Tags: CASE REPORT Source Type: research
